scholarly journals T cell growth factors from adult T cell leukemia virus-transformed cell lines

FEBS Letters ◽  
1984 ◽  
Vol 177 (2) ◽  
pp. 200-204 ◽  
Author(s):  
Yasuji Okai ◽  
Takashi Oka ◽  
Tadaatsu Akagi ◽  
Sayuri Kurata ◽  
Nobuo Fujiyoshi
2007 ◽  
Vol 120 (10) ◽  
pp. 2251-2261 ◽  
Author(s):  
Taeko Okudaira ◽  
Mitsuomi Hirashima ◽  
Chie Ishikawa ◽  
Shoko Makishi ◽  
Mariko Tomita ◽  
...  

1984 ◽  
Vol 34 (1) ◽  
pp. 77-82 ◽  
Author(s):  
Naoki Yamamoto ◽  
Nobuyuki Kobayashi ◽  
Kaoru Takeuchi ◽  
Yoshio Koyanagi ◽  
Masakazu Hatanaka ◽  
...  

Life ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 127
Author(s):  
Norbert Kassay ◽  
János András Mótyán ◽  
Krisztina Matúz ◽  
Mária Golda ◽  
József Tőzsér

The human T-lymphotropic viruses (HTLVs) are causative agents of severe diseases including adult T-cell leukemia. Similar to human immunodeficiency viruses (HIVs), the viral protease (PR) plays a crucial role in the viral life-cycle via the processing of the viral polyproteins. Thus, it is a potential target of anti-retroviral therapies. In this study, we performed in vitro comparative analysis of human T-cell leukemia virus type 1, 2, and 3 (HTLV-1, -2, and -3) proteases. Amino acid preferences of S4 to S1′ subsites were studied by using a series of synthetic oligopeptide substrates representing the natural and modified cleavage site sequences of the proteases. Biochemical characteristics of the different PRs were also determined, including catalytic efficiencies and dependence of activity on pH, temperature, and ionic strength. We investigated the effects of different HIV-1 PR inhibitors (atazanavir, darunavir, DMP-323, indinavir, ritonavir, and saquinavir) on enzyme activities, and inhibitory potentials of IB-268 and IB-269 inhibitors that were previously designed against HTLV-1 PR. Comparative biochemical analysis of HTLV-1, -2, and -3 PRs may help understand the characteristic similarities and differences between these enzymes in order to estimate the potential of the appearance of drug-resistance against specific HTLV-1 PR inhibitors.


1984 ◽  
Vol 173 (1) ◽  
pp. 57-64 ◽  
Author(s):  
N. Yamamoto ◽  
M. Hayami ◽  
A. Komuro ◽  
J. Schneider ◽  
G. Hunsmann ◽  
...  

2016 ◽  
Vol 27 (9) ◽  
pp. 1059-1066 ◽  
Author(s):  
Hisayoshi Kondo ◽  
Midori Soda ◽  
Norie Sawada ◽  
Manami Inoue ◽  
Yoshitaka Imaizumi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document